AVXL — ANAVEX LIFE SCIENCES CORP.

—
Nasdaq · Health Care · Biotechnology · CIK 1314052 ·
Last close
$0.74
Market Cap
$68.60M
52W High
$5.36
52W Low
$0.71
ADV30
1,269,521
Next earnings
2026-11-24

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — 6,771,000 7,824,000 120,139,000 118,326,000 7,692,000
Mar 2026 0 — -6,457,000 -5,338,000 128,766,000 127,422,000 7,059,000
Dec 2025 0 — -6,782,000 -5,681,000 132,989,000 131,749,000 6,371,000
Sep 2025 0 — -11,479,000 -9,827,000 103,815,000 102,577,000 8,946,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-34,075,000
Investing CF
—
Financing CF
$45,049,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.39
As of
2026-08-30

Balance + Analyst (yfinance extras)

Retained Earnings
$-388,129,000
Inventory
—
Receivables
$844,000
ST Investments
—
EBIT TTM
$-39,991,000
Pretax Income TTM
$-39,929,000
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 0 -51,371,000 -46,377,000 103,815,000 8,946,000 94,869,000 -39,044,000
Sep 2024 0 -52,802,000 -43,002,000 135,567,000 15,304,000 120,263,000 -30,812,000
Sep 2023 0 -55,738,000 -47,505,000 154,386,000 12,534,000 141,852,000 -27,785,000
Sep 2022 0 -50,986,000 -47,978,000 152,705,000 10,214,000 142,491,000 -24,238,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-13,022,000
OpCashFlow TTM
—
Assets (Latest)
$120,139,000
Forward EPS
$-0.55

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.00 · spot: $0.72 · call volume: 20 · put volume: 1
Expected Move to 2027-01-15: ±$0.40 (55.63%) — implied range $0.32 – $1.12 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ATRA Atara Biotherapeutics, Inc. $66.22M $6.50 —
CRDF Cardiff Oncology, Inc. $65.85M $0.85 —
TNYA Tenaya Therapeutics, Inc. $73.58M $0.32 —
CSBR CHAMPIONS ONCOLOGY, INC. $63.91M $4.59 —
CHRS Coherus Oncology, Inc. $73.95M $0.48 —

News headlines (Yahoo Finance, 1h cache)

Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
2026-11-03 12:00 · Yahoo
Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
2026-10-20 20:00 · Yahoo
Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial
2026-10-16 13:33 · Yahoo
Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
2026-10-15 20:00 · Yahoo
Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
2026-09-24 14:00 · Yahoo
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
2026-09-18 13:48 · Yahoo
PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance
2026-09-14 23:30 · Yahoo
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
2026-09-10 18:45 · Yahoo
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
2026-09-08 12:00 · Yahoo
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
2026-09-03 21:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.